Optimal therapy in genotype 4 chronic hepatitis C: Finally cured?

Liver International

Volumn 35, Issue s1, 2015, Pages 27-34

  Abdel Razek, Wael ^a   Waked, Imam ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Direct acting antivirals; Genotype 4; Hepatitis C; Interferon free regimens

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BECLABUVIR; DACLATASVIR; DANOPREVIR; ELBASVIR; GRAZOPREVIR; GS 5816; INTERLEUKIN 28B; LEDIPASVIR; LEDIPASVIR PLUS SOFOSBUVIR; MERICITABINE; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; UNCLASSIFIED DRUG; VEDROPREVIR; BMS-790052; HETEROCYCLIC COMPOUNDS, 3-RING; IMIDAZOLES; INTERFERON-ALPHA; NS-5 PROTEIN, HEPATITIS C VIRUS; PEGINTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SULFONAMIDES; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG TREATMENT FAILURE; GENOTYPE; HEPATITIS C; HETEROZYGOTE; HUMAN; INSULIN RESISTANCE; PRACTICE GUIDELINE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG THERAPY, COMBINATION; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; METHODS; TRENDS;

DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SULFONAMIDES; URIDINE MONOPHOSPHATE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84919653420     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12724     Document Type: Review

References (51)

1. Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014; 39: 137-47.
2. Mohd HK, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.
3. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000; 182: 698-707.
4. Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepatitis 2014; 21(Suppl. 1): 34-59.
5. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: the GEMHEP GenoCII Study. J Viral Hepatitis 2005; 12: 405-13.
6. Fernandez-Arcas N, Lopez-Siles J, Trapero S, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006; 78: 1429-35.
7. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-62.
8. Irshad M, Ansari MA, Singh A, et al. HCV-genotypes: a review on their origin, global status, assay system, pathogenecity and response to treatment. Hepatogastroenterology 2010; 57: 1529-38.
9. Poordad F, Mccone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
10. Jacobson IM, Mchutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
11. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
12. European Public Assessment Report (EPAR) for Olysio. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002777/WC500167869.pdf. Accessed: 1 September 2014.
13. BMS Press Release. Available at http://news.bms.com/press-release/rd-news/european-commission-approves-bristol-myers-squibbs-daklinza-daclatasvir-across. Accessed 1 September 2014.
14. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56: 2039-50.
15. Doss W, Mohamed MK, Esmat G, et al. Egyptian national control strategy for viral hepatitis 2008-2012. Arab Republic of Egypt, Ministry of Health and Population, National Committee for the Control of Viral Hepatitis. Available at http://www.hepnile.org/images/stories/doc/NSP_10_April_2008_final2.pdf. Accessed 1 September 2014.
16. Esmat G, El Kassas M, Hassany M, Gamil M, El Raziky M. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int 2014; 34(Suppl. 1): 24-8.
17. Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 1112-9.
18. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-9.
19. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepatitis 2007; 14: 460-7.
20. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.
21. De Nicola S, Aghemo A, Rumi MG, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55: 336-42.
22. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-54.
23. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
24. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-62.
25. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
26. Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-33.
27. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-53.
28. Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naive or treatment-experienced chronic HCV genotype 4-infected patients: final results of a phase III trial. J Hepatol 2014; 60: S535 (Abstract P1319).
29. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 2014; doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print]
30. Ruane PJ, Ain D, Meshrekey R, et al. Sofosbuvir plus ribavirin, an interferon-free regimen, in the treatment of treatment-naïve and treatment-experienced patients with chronic genotype 4 HCV infection. J Hepatol 2014; 60: S503-4 (Abstract P1243).
31. Esmat GE, Shiha G, Omar RF, et al. Sofosbuvir Plus Ribavirin in the Treatment of Egyptian Patients with Chronic Genotype 4 HCV Infection. Boston, MA: AASLD, 2014 (Abstract).
32. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010; 2: 30ra32.
33. Mccormick AL, Wang L, Garcia-Diaz A, et al. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4. Antivir Ther 2014; doi: 10.3851/IMP2763 [Epub ahead of print]
34. Rajyaguru S, Xu S, Hebner C, et al. Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance associated variants selected by other classes of antiviral inhibitors. Hepatology 2013; 58: 739 (Abstract 1094).
35. Han B, Mo H, Wong KA. In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir (GS-7977), no cross resistance to other classes of direct-acting antivirals, and hypersensitivity to ribavirin. Hepatology 2012; 56: 711A-2A (Abstract 1078).
36. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
37. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N Engl J Med 2014; 370: 1889-98.
38. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23.
39. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146: 736-43.
40. Kapoor R, Kohli A, Sidharthan S, et al. All Oral Treatment for Genotype 4 Chronic Hepatitis C Infection with Sofosbuvir and Ledipasvir: Interim Results from the NIAID SYNERGY Trial. Boston, MA: AASLD, 2014 (Abstract).
41. Everson GT, Tran TT, Towner WJ, et al. Safety and efficacy of treatment with interferon-free, ribavirin-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment-naïve patients with genotypes 1-6 HCV infection. J Hepatol 2014; 60: S46 (Abstract O111).
42. Hezode C, Marcellin P, Pol S, et al. Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/r + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. J Hepatol 2014; 60: S24 (Abstract O58).
43. Hassanein T, Sims K, Bennett M, et al. All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection. J Hepatol 2014; 60: S472 (Abstract P1163).
44. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol 2014; 60: S28 (Abstract O68).
45. Obach D, Deuffic-Burban S, Esmat G, et al. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis 2014; 58: 1064-71.
46. Reuters. Gilead offers Egypt new hepatitis C drug at 99 percent discount. Available at http://www.reuters.com/article/2014/03/21/us-hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321. Accessed 11 September 2014.
47. Umar M, Khan AG, Abbas Z, et al. World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013. J Clin Gastroenterol 2014; 48: 204-17.
48. WHO. World Health Organization: Guidelines for the screening, care and treatment of persons with hepatitis C infection. Available at http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1. Accessed 11 September 2014.
49. Gilead Sciences Prices Sovaldi in India at a Tiny Fraction of U.S. Cost. Available at http://www.fiercepharma.com/story/gilead-sciences-prices-sovaldi-india-tiny-fraction-us-cost/2014-08-07. Accessed 11 September 2014.
50. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org. Accessed 11 September 2014.
51. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.